Searchable abstracts of presentations at key conferences in endocrinology

ea0064026 | An adrenal tumor with gynecomastia | BES2019

An adrenal tumor with gynecomastia

De Herdt C , Philipse E , De Block C

Initial presentation and work-up: A 42-year-old man was referred to the endocrinologist because of an incidentaloma of the right adrenal with a maximum diameter of 4.2 cm on echography of the abdomen. Echography was performed because the patient presented with icterus. An abdominal CT scan confirmed a right adrenal mass with a maximum diameter of 5.1 cm. The intensity of the adrenal adenoma amounted 39 Hounsfield units. The patient did not have a significant medical history, e...

ea0079011 | Abstracts | BES2021

A cross-sectional analysis of the association between testosterone and biopsy-proven non-alcoholic fatty liver disease in 134 obese men

Herdt C De , Block C De , A Verrijken , Dessel K Van , S Francque , L Van Gaal , E Dirinck

Background and aims: Low levels of testosterone and non-alcoholic fatty liver disease (NAFLD) in obese men are both linked to the metabolic syndrome, but the independent association between testosterone and NAFLD needs to be elucidated. In this cross-sectional analysis the association between total testosterone (total T) and calculated free testosterone (cFT) on the one hand and NAFLD, non-alcoholic steatohepatitis (NASH) and fibrosis on the other hand was investigated in obes...

ea0029p1408 | Pituitary Clinical | ICEECE2012

Pasireotide treatment is associated with clinically meaningful improvements in health-related quality of life in Cushing’s disease: results from a large, randomized, double-blind phase III trial

Webb S , Badia X , Zgliczynski W , Portocarrero-Ortiz L , Maldonado M , Trovato A , Forsythe A , Nelson L , McLeod L , De Block C , Gadelha M

Introduction: Patients with Cushing’s disease have significantly impaired health-related quality of life (HRQoL). Effective treatment is needed to treat Cushing’s disease and improve HRQoL; however, there are currently no approved medical treatments for Cushing’s disease. The effect of pasireotide on HRQoL in patients with Cushing’s disease was evaluated as part of a randomized, phase III study.Methods: Patients with persistent/recurr...

ea0064010 | Effect of nationwide reimbursement of sensor-augmented pump therapy in a paediatric type 1 diabetes population on HBA1C, hypoglycaemia and quality of life: the rescue-paediatrics study | BES2019

Effect of nationwide reimbursement of sensor-augmented pump therapy in a paediatric type 1 diabetes population on HBA1C, hypoglycaemia and quality of life: The rescue-paediatrics study

De Ridder F , Charleer S , Jacobs S , Casteels K , Van Aken S , Vanbesien J , Gies I , Massa G , Lysy P , Logghe K , Lebrethon M-C , Depoorter S , Ledeganck K , Gillard P , De Block C , den Brinker M

Background: Long-term real-life data of sensor-augmented pump therapy (SAP) in paediatric type 1 diabetes (T1D) patients are lacking.Objectives: To assess the impact of SAP in a nationwide study of paediatric T1D patients on HbA1c, hypoglycaemia and quality of life until 24 months.Methods: Between December 2014 an...